Mar 21, 2024 7:00am EDT Cabaletta Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Mar 20, 2024 7:00am EDT Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Systemic Sclerosis